Explore the evolving landscape of medicinal cannabis in Australia, examining clinical evidence, access pathways, and expert ...

The Neurobiochemistry Laboratory at the Neurosciences Centre (NSC), All India Institute of Medical Sciences (AIIMS), has launched specialised Therapeutic Drug Monitoring (TDM) services for the ...

Actio Biosciences has begun the KYRON Phase Ib/II trial of ABS-1230, a selective oral KCNT1 inhibitor, for KCNT1-related epilepsy.

AIIMS launches advanced Therapeutic Drug Monitoring facility to enhance epilepsy care and accessibility for patients across India.

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion transaction that expands its presence in the US rare ...

Angelini Pharma has signed a definitive agreement to acquire Catalyst Pharmaceuticals for a total equity value of nearly $4.1bn.

Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...

The deal marks the company’s first acquisition since 2021 and a major step forward in its mission to become a global leader ...

Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for Tuberous ...

Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on ...